Life scientists identify drug that could aid treatment of anxiety disorders

February 21, 2013 by Stuart Wolpert

(Medical Xpress)—The drug scopolamine has been used to treat a variety of conditions, including nausea and motion sickness. A new study by UCLA life scientists suggests that it may also be useful in treating anxiety disorders.

Researchers found that the drug can help boost the effectiveness of a common treatment for known as exposure therapy. In exposure therapy, a subject with a phobia or anxiety is repeatedly exposed to the object or situation they fear, in a non-threatening setting. The goal of this treatment is to ultimately lessen and eliminate the fear — in essence, make it "extinct."

However, fear- memories formed during this type of therapy tend to be weak because they are tied to the non-dangerous context. Subjects have a tendency to relapse when they again encounter the source of their anxiety in a different environment.

"Extinction has one Achilles heel that at present has not quite been pierced — namely, extinction learning is highly dependent on the environment or context in which it occurs," said Michael Fanselow, a UCLA professor of psychology and the senior author of the study. "This makes memories formed during extinction highly fragile and susceptible to fear-recovery or relapse in any non-extinction environment."

In their new study, published Feb. 15 in the in the journal Biological Psychiatry, Fanselow and his colleagues attempted to overcome this challenge by administering in conjunction with the exposure therapy.

"We took an entirely novel by targeting extinctions' context-dependency and attempting to unbind extinction from its contextual bond," said Fanselow, who holds UCLA's Eleanor Leslie Term Chair in Innovative Neuroscience. "Using a non-invasive and readily translatable pharmacological agent, scopolamine, to block cholinergic transmission and hence, contextual processing, we discovered that fear-recovery after extinction could be thwarted."

Fanselow and his team were able to disrupt contextual processing in rats during anxiety-extinction by using low doses of the drug.

"This finding provides groundbreaking evidence that changing the nature of extinction learning, rather then its magnitude, can produce profound improvements in the prevention of relapse," Fanselow said.

The research, while still preliminary, suggests that scopolamine may be an effective pharmacological adjunct to .

Explore further: Scopolamine: An old drug with new psychiatric applications

Related Stories

Recommended for you

The birth of politics in children—the case of dominance

September 26, 2016

As they grow up, do children become young Robin Hoods? Depending on their age, they do not allocate resources in the same way between dominant and subordinate individuals. Thus a tendency towards egalitarianism develops and ...

Oxytocin enhances spirituality, new study says

September 21, 2016

Oxytocin has been dubbed the "love hormone" for its role promoting social bonding, altruism and more. Now new research from Duke University suggests the hormone may also support spirituality.

Study reveals a biological link between stress and obesity

September 21, 2016

Metabolic and anxiety-related disorders both pose a significant healthcare burden, and are in the spotlight of contemporary research and therapeutic efforts. Although intuitively we assume that these two phenomena overlap, ...

Men with anxiety are more likely to die of cancer, study says

September 20, 2016

Men over 40 who are plagued with the omnipresent of generalized anxiety disorder are more than twice as likely to die of cancer than are men who do not have the mental affliction, new research finds. But for women who suffer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.